The share price of Arbutus Biopharma Corporation (NASDAQ:ABUS) fell to $2.56 per share on Wednesday from $2.65. While Arbutus Biopharma Corporation has underperformed by -3.40%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ABUS rose by 6.67%, with highs and lows ranging from $3.14 to $1.85, whereas the simple moving average jumped by 0.29% in the last 200 days.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Analysis of Arbutus Biopharma Corporation (ABUS)
Further, the quarter-over-quarter decrease in sales is -46.80%, showing a negative trend in the upcoming months.
To gain a thorough understanding of Arbutus Biopharma Corporation’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -48.30% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 6.10, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and ABUS is recording an average volume of 890.11K. On a monthly basis, the volatility of the stock is set at 3.73%, whereas on a weekly basis, it is put at 3.85%, with a gain of 1.59% over the past seven days. Furthermore, long-term investors anticipate a median target price of $5.40, showing growth from the present price of $2.56, which can serve as yet another indication of whether ABUS is worth investing in or should be passed over.
How Do You Analyze Arbutus Biopharma Corporation Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 25.22%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 30.00% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in ABUS shares?
The recent increase in stakes in ABUS appears to be a result of several institutional investors and hedge funds increasing their positions. BlackRock Fund Advisors’s position in ABUS has decreased by -3.19% in the first quarter. The company now owns 7,763,758 shares of the stock, with a value of $19.49 million, following the sale of -256,014 additional shares during the last quarter. Whitefort Capital Management, LP made another increased to its shares in ABUS during the first quarter, upping its stake by 94.77%. During the last quarter, the company dropped down 3,649,257 additional shares for a total stake of worth $18.83 million, bringing number of shares owned by the company to 7,500,026.
During the first quarter, Two Seas Capital LP subtracted a -39,469 position in ABUS. The Vanguard Group, Inc. purchased an additional 0.28 million shares in the last quarter, increasing its holdings by 5.29%, now holding 5.48 million shares worth $13.76 million. At the end of the first quarter, Morgan Stanley Investment Managem increased its ABUS holdings by 493,176.49% and now holds 4.47 million ABUS shares valued at $11.22 million with the added 4.47 million shares during the period. ABUS shares are owned by institutional investors to the tune of 30.00% at present.
